Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Blood (2024) 144 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2024-206919

Published: 2024

Journal Articles

Targeting of the CD161 Inhibitory Receptor Enhances Bone Marrow-Resident Memory CD8 + T Cell-Mediated Immunity Against Multiple Myeloma

Liwen Wang, Linzhi Xie, Yi Zhou, Yan Yu, Shiming Tan, Qian Cheng, Rong He, Xin Li

Blood (2024) 144 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2024-198964

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation

Gao Yuang, Qianyu Zhang, Zhichun Lv, Shuhong Liu, Yide Sun, Huiying Gao, Xiongwei Zhao, Xin Li, Yang Xue, Hao Li, Changyan Li, Hongmei Ning

Blood (2024) 144 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2024-206794

Published: 2024

Journal Articles

Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

QI Deng, Xin Li, Qing Li, Jia Wang, Juan Mu, Rui Cui

Blood (2024) 144 (Supplement 1): 4763.

https://doi.org/10.1182/blood-2024-205268

Published: 2024

Journal Articles

Pretreatment with BTK Inhibitors Could Improve the Sensitivity of DLBCL Cells to CAR-T Cells in Co-Culture System By Down-Regulating the Polarization of M2 Macrophages

Yao Qi, Jia Wang, Xin Li, Juan Mu, Rui Cui, QI Deng

Blood (2024) 144 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2024-206729

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Qian Cheng, JingWen Tan, Rui Liu, Liqing Kang, Hongjia Zhu, Yi Zhang, Erhua Wang, Ying Li, Jian Zhang, Han Xiao, Rong He, Xiaoyan Lou, Nan Xu, Wei Wang, Zhou Yu, Minghao Li, Hongfei Gu, Lei Yu, Xin Li

Blood (2024) 144 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2024-200516

Published: 2024

Journal Articles

Targeted Next Generation Sequencing Is Comparable with Metagenomic Next Generation Sequencing in Hematological Malignancies with Suspected Pneumonia for Pathogenic Microorganism Detection

Yishu Tang, Xiao Yulian, Rong He, Xin Li

Blood (2024) 144 (Supplement 1): 5993.

https://doi.org/10.1182/blood-2024-207266

Published: 2024

Journal Articles

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Na Yao, Xin Li, Jing Yang, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6541.

https://doi.org/10.1182/blood-2024-203548

Published: 2024

Journal Articles

Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy

Blood (2024) 144 (Supplement 1): 6458.

https://doi.org/10.1182/blood-2024-202107

Published: 2024

Journal Articles

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Xin Li, Jia Wei, Dong-feng Zeng, Shu-nan Qi, Bingzong Li, Wei Guo, Li Wang, Yajun Li, Xudong Zhang, Yong Yang, Shukai Qiao, Yan Zeng, Yunfei Song, Jing-wen Wang, Jian-min Ma, Liang Wang

Blood (2024) 144 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2024-206489

Published: 2024

Journal Articles

A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part

Lei Yang, Xin Li, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6413.

https://doi.org/10.1182/blood-2024-207469

Published: 2024

Journal Articles

Outcomes and Prognostic Factors of the Alternative Regimens for Angioimmunoblastic T Cell Lymphoma: A Retrospective Study

Jiaqin Yan, Bingjie Wang, Yankui Wei, Shasha Zhang, Lei Zhang, Ling Li, Xin Li, Xiaorui Fu, Xinhua Wang, Zhenchang Sun, Xudong Zhang, Mingzhi Zhang

Blood (2024) 144 (Supplement 1): 6408.

https://doi.org/10.1182/blood-2024-206732

Published: 2024

Journal Articles

Limited Quality of Life Sacrifice for Optimizing Long-Term Survival: The Impact of p-Alg Compared to r-ATG in High-Risk Hematological Malignancy Patients Undergoing Matched Sibling Donor Transplantation

Qian Cheng, Lingyan Yan, Xin Li

Blood (2024) 144 (Supplement 1): 7359.

https://doi.org/10.1182/blood-2024-203026

Published: 2024

Journal Articles

Changes in Intensive Care Unit Mortality and Treatment Patterns in Acute Leukemia Patients over a 16-Year Period in China

Linli Lu, Qian Cheng, Xin Li

Blood (2024) 144 (Supplement 1): 5854.

https://doi.org/10.1182/blood-2024-203162

Published: 2024

Journal Articles

High Efficacy of Adding G-CSF to Venetoclax Plus Azacitidine As Front-Line Treatment in Previously Untreated Acute Myeloid Leukaemia:a Pilot Study

Blood (2024) 144 (Supplement 1): 7689.1.

https://doi.org/10.1182/blood-2024-207140

Published: 2024

Journal Articles

BCMA CAR-T-Cell Therapy in Combination with Long-Term Pomalidomide Is a Safe and Effective Treatment for Relapsed/Refractory Multiple Myeloma

Yuhan Yan, Yixuan Tu, De-Pei Wu, Xin Li

Blood (2023) 142 (Supplement 1): 2116.

https://doi.org/10.1182/blood-2023-181573

Published: 2023

Journal Articles

Circulating Exosomal miRNA Signature As a Potential Risk Factor for DNA Virus Infection in Patients with Multiple Myeloma

Xin Chen, Liwen Wang, Zuqun Deng, Yishu Tang, Qian Cheng, Depei Wu, Xin Li

Blood (2023) 142 (Supplement 1): 1926.

https://doi.org/10.1182/blood-2023-185287

Published: 2023

Journal Articles

Efficacy and Safety of Chemotherapy (DDGP vs VIPD) Followed Radiotherapy Vs Radiotherapy Followed Chemotherapy (DDGP vs VIPD) Vs Radiotherapy Alone for Newly Diagnosed Early Stage Extranodal Natural Killer/T Cell Lymphoma: Final Results of a Prospective, Multicenter, Randomized, Controlled Clinical Trial

Mingzhi Zhang, Lei Zhang, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Yu Chang, Xudong Zhang, Hui Yu, Feifei Nan, Zhiyuan Zhou, Xiyang Liu, Xiaolong Wu, Liqun Zou, Hui Zhou, Hongwei Xue

Blood (2023) 142 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2023-188245

Published: 2023

NARROW

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Targeting of the CD161 Inhibitory Receptor Enhances Bone Marrow-Resident Memory CD8 + T Cell-Mediated Immunity Against Multiple Myeloma

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation

Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Pretreatment with BTK Inhibitors Could Improve the Sensitivity of DLBCL Cells to CAR-T Cells in Co-Culture System By Down-Regulating the Polarization of M2 Macrophages

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Targeted Next Generation Sequencing Is Comparable with Metagenomic Next Generation Sequencing in Hematological Malignancies with Suspected Pneumonia for Pathogenic Microorganism Detection

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part

Outcomes and Prognostic Factors of the Alternative Regimens for Angioimmunoblastic T Cell Lymphoma: A Retrospective Study

Limited Quality of Life Sacrifice for Optimizing Long-Term Survival: The Impact of p-Alg Compared to r-ATG in High-Risk Hematological Malignancy Patients Undergoing Matched Sibling Donor Transplantation

Changes in Intensive Care Unit Mortality and Treatment Patterns in Acute Leukemia Patients over a 16-Year Period in China

High Efficacy of Adding G-CSF to Venetoclax Plus Azacitidine As Front-Line Treatment in Previously Untreated Acute Myeloid Leukaemia:a Pilot Study

BCMA CAR-T-Cell Therapy in Combination with Long-Term Pomalidomide Is a Safe and Effective Treatment for Relapsed/Refractory Multiple Myeloma

Circulating Exosomal miRNA Signature As a Potential Risk Factor for DNA Virus Infection in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only